If you’re experiencing health or medical complications, stem cell therapy may be one of the options you are considering. Stem cell procedures can be used to address a variety of health issues. The question is, how do you know that stem cell therapy will work for you? And how can you be sure that the provider you’ve chosen is the best one for your case? [Read more…]
Human Induced Pluripotent Stem Cell (iPSC) Derived Tissues – Present & Future Outlook
In this article, the present and future outlook for human iPSC-derived tissues is explored. Induced pluripotent stem cells (iPSCs) are differentiated cells that are reprogrammed into a pluripotent state, allowing a wide range of cell and tissue types to be derived from them.
Key findings include:
- iPSC technology is moving from a boutique phenomenon to industrialized cellular models.
- Increasing recognition by industry and regulatory bodies for detecting a variety of toxicities.
- Emerging utility for predicting cardio and neuro-related oncology adverse effects.
Inside the iPSC Industry: Growth, Trends, and Future Directions
Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells by Shinya Yamanaka’s lab at Kyoto University in Japan was the first instance in which there was successful generation of iPSCs.[1] In 2007, a series of follow-up experiments was done at Kyoto University in which human adult cells were transformed into iPSC cells. [2] Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.[3] [Read more…]
Legendary NFL Quarterback Bernie Kosar Launches X Pro. Athlete Cognitive Longevity Wellness Program to Push the Limits of Brain Performance with Crowley Center for Regenerative Biotherapeutics in collaboration with global biotech manufacturer Regenerelle®, LLC, and trial sponsor The Crowley Center for Regenerative Biotherapeutics, LLC.
Backed by a $10M Age Zero™ Regenerelle® in-kind contribution by the Crowley Family, Team Bernie™ brings together NFL veterans and longevity innovators to explore next-generation cognitive optimization.
COLUMBUS, OH / FORT LAUDERDALE, FL / ROCHESTER, NY, October 23, 2025 – In a world focused on optimizing the body — from cold plunges to peptides — one team is taking on the next frontier: the brain.
Renewing Athletes’ Lives™ (RAL), co-founded by Michael Crowley, Erin Crowley, and Bernie Kosar, today announced the launch of Team Bernie™, a Cognitive Longevity Program exploring how targeted brain-support strategies may help athletes sharpen focus, clarity, and mental resilience long after their playing careers ends. [Read more…]
The Rise of Exosome-Based Cosmeceuticals in 2026
A cosmeceutical is defined as a product that is marketed as a cosmetic but has the capacity to exert pharmaceutical effects. In recent years, exosomes have been utilized within the global cosmetics industry to manufacture and market skincare products that use the power of these small extracellular vesicles to enhance a broad range of traits, including but not limited to skin health and rejuvenation, scar improvement, hair regrowth, anti-aging effects, and beyond. Exosomes can provide bioactive substances such as proteins, lipids, and nucleic acids to the target cells to alter gene expression and cellular function. Importantly, exosomes can also induce collagen formation, enhance tissue regeneration, and exert anti-inflammatory properties. [Read more…]
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 334
- Next Page »